High Flow Nasal Cannula for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether a high flow nasal cannula can make certain lung procedures smoother and quicker. The focus is on reducing interruptions and breathing issues during a specific lung cancer procedure. Participants will receive oxygen through either a high flow nasal cannula or a regular one. The trial seeks individuals planning to undergo an EBUS bronchoscopy who typically receive moderate sedation. Those with a history of nasal surgery or specific breathing issues may not be suitable candidates. As an unphased trial, this study offers a unique opportunity to contribute to advancements in lung procedure techniques.
Do I need to stop taking my current medications for the trial?
The trial requires that you stop taking any blood thinners (anticoagulation medications) before the procedure. For other medications, the protocol does not specify, so it's best to discuss with the trial team.
What prior data suggests that the high flow nasal cannula is safe for use during procedures?
Research has shown that high flow nasal cannula (HFNC) is generally safe and well-tolerated by patients. Studies have found that HFNC can improve oxygen levels and reduce the need for reintubation. It is also associated with shorter hospital stays and less dryness in the nose and mouth compared to other oxygen therapies. Importantly, HFNC does not increase the risk of lung infections or death compared to other treatments. Overall, evidence suggests that HFNC is a reliable and safe method for delivering oxygen to patients, including those with cancer.12345
Why are researchers excited about this trial?
Researchers are excited about high flow nasal cannula oxygen because it offers a new way to support lung cancer patients during procedures. Unlike regular nasal cannulas, which deliver oxygen at a lower flow rate, the high flow nasal cannula provides a higher oxygen concentration using a Vapotherm device. This method can enhance comfort and improve oxygen levels more efficiently, potentially leading to better outcomes and quicker recovery for patients. By delivering humidified and heated oxygen, it may also reduce airway dryness and irritation, which are common issues with standard oxygen therapy.
What evidence suggests that the high flow nasal cannula is effective for lung cancer procedures?
Research has shown that high flow nasal cannula (HFNC) therapy can effectively assist patients during breathing treatments. One study found that patients who successfully used HFNC had a 94% survival rate in the hospital, while those for whom HFNC was ineffective had a 0% survival rate. HFNC also correlates with shorter hospital stays and less discomfort, such as dryness in the nose and mouth. For cancer patients, HFNC may alleviate breathing problems and enhance quality of life. In this trial, participants will receive either HFNC or a regular nasal cannula during procedures. These findings suggest that HFNC could make procedures like bronchoscopy safer and more comfortable by reducing interruptions and instances of oxygen level drops.23678
Are You a Good Fit for This Trial?
This trial is for patients scheduled to undergo an EBUS bronchoscopy with moderate conscious sedation. It's designed to see if a high flow nasal cannula can improve the procedure compared to using a regular nasal cannula.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo EBUS bronchoscopy with either high flow nasal cannula or regular nasal cannula under monitored anesthesia care
Follow-up
Participants are monitored for safety and effectiveness after the procedure
What Are the Treatments Tested in This Trial?
Interventions
- High Flow Nasal Cannula
Trial Overview
The study compares two types of oxygen delivery during EBUS bronchoscopy: a standard nasal cannula versus Vapotherm, which provides high-flow heated and humidified air. The goal is to determine if Vapotherm reduces interruptions, hypoxia, and overall procedure time.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
High flow nasal cannula oxygen will be provided during the procedure using a Vapotherm device
Regular nasal cannula oxygen will be provided during the procedure
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Cooper Health System
Lead Sponsor
Citations
Monitoring the Efficacy of High-Flow Nasal Cannula Oxygen ...
Patients with successful HFNC treatment had better in-hospital survival (94%) compared to those with failed HFNC treatment (0%, p < 0.001).
Use of high‐flow nasal cannula oxygen therapy for patients ...
Patients received HFNC therapy for a mean of 3.4 days in the last 2 weeks of life, and 62.6% initiated it within 4 days before death.
Outcomes of high-flow versus conventional oxygen therapy ...
HFNC was associated with shorter hospital LOS and lower rates of nose/mouth dryness compared to other non-invasive oxygen techniques.
High Flow Nasal Cannula oxygen therapy for Do-Not-Intubate ...
Conclusion: HFNC maybe improve dyspnea in DNI patients with advanced cancer. Also, some cases suggest the efficacy for QOL. Our prospective study for evaluation ...
High Flow Nasal Cannula in Patients With Cancer at the ...
Only 16% (95% CI: 13–20) of the patients were discharged alive. Liberation from HFNC by day three and overall was accomplished in 23% and 25% of ...
Effect of heated humidified high-flow nasal cannula (HFNC ...
Conclusion: HFNC oxygen therapy has good effect, high safety, and is easy to be accepted by dyspnea patients with advanced cancer. It can be used as the first ...
Meta-analysis of high-flow nasal cannula oxygen therapy ...
Conclusion: HFNC can improve PaO2 and OI, reduce PaCO2, re-intubation rate, and length of stay in ICU, with no difference in pulmonary infection or mortality ...
High-flow nasal cannula for respiratory failure in adult ...
The groups exhibited similar 90-day mortality rates (HFNC, 21.2%; conventional oxygen treatment, 17.4%). The conflicting results between the ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.